Company

Pipeline

Everist Genomics is leading the evolution of a new era in medicine: Personalized treatment tailored to each patient’s unique genetic make-up and disease characteristics. 

Using proprietary applications based on molecular biomarkers and novel sensor technology, the company has developed and commercialized a portfolio of prognostic tests aimed at disease states with substantial unmet medical needs such as cancer and cardiovascular illness. Everist Genomics gives physicians crucial information about a patient’s health that can be used to make definitive treatment decisions and measure disease progression.

EGI has a compelling portfolio of six innovative market-ready products and three development platform technologies; EGI expects to launch an additional 3+ new products in each of the next 5 years.


 

EGI products are focused on rapidly growing disease areas with major unmet needs, including cancer, cardiovascular disease and metabolic disease (e.g. diabetes).

EGI Disease Area Focus EGI Market-Ready Products Regulatory Status Estimated Eligible
Market for EGI Product
Cardiovascular Disease (CVD)
  1. CardioDefender; the world’s only hospital quality ECG on a smartphone; for early diagnosis and treatment of life threatening heart arrhythmias
  2. AngioDefender ; the world’s first non-invasive proprietary sensor technology for early-stage diagnosis of atherosclerosis and CVD in asymptomatic patients
  • FDA and European CE Mark Approved
  • Canadian Regulatory Approval Filed
  1. All people aged 40+; ~849 million eligible customers within EGI Big Four
  2. All men and women aged 25 + for annual screening and monitoring
Cancer
  1. OncoDefender-CRC; assists physicians in identifying early-stage colorectal cancer patients likely to benefit from adjuvant chemotherapy
  2. OncoSelector; a companion diagnostic to OncoDefender, OncoSelector enables physicians to determine which chemo-therapy a colorectal patient will best tolerate and respond to
  3. OncoDefender-MMR; assists physicians in assessing prognosis and defining optimal treatment for colorectal cancer patients
  4. OncoDefender-Lynch Syndrome; identifies patients with high life-time risk of developing one of several types of cancer
  • Approved
  • Approved
  • Approved
  • Approved
  1. ~750,000 patients/yr
  2. ~1 million patients/yr
  3. ~5 million patients/yr
  4. ~5 million patients/yr